258 related articles for article (PubMed ID: 9856813)
1. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.
Huang SK; Okamoto T; Morton DL; Hoon DS
J Invest Dermatol; 1998 Oct; 111(4):662-7. PubMed ID: 9764850
[TBL] [Abstract][Full Text] [Related]
3. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune etiology of generalized vitiligo.
Le Poole IC; Luiten RM
Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
Fishman P; Merimski O; Baharav E; Shoenfeld Y
Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
[TBL] [Abstract][Full Text] [Related]
7. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
Cui J; Bystryn JC
Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
[TBL] [Abstract][Full Text] [Related]
8. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-associated hypopigmentation: where are the antibodies?
Merimsky O; Shoenfeld Y; Baharav E; Altomonte M; Chaitchik S; Maio M; Ferrone S; Fishman P
Am J Clin Oncol; 1996 Dec; 19(6):613-8. PubMed ID: 8931683
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
12. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
Li YL; Yu CL; Yu HS
J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
[TBL] [Abstract][Full Text] [Related]
13. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
14. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
Takeuchi H; Kuo C; Morton DL; Wang HJ; Hoon DS
Cancer Res; 2003 Jan; 63(2):441-8. PubMed ID: 12543800
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo.
Zhu MC; Liu CG; Wang DX; Zhan Z
Genet Mol Res; 2015 Dec; 14(4):16060-73. PubMed ID: 26662399
[TBL] [Abstract][Full Text] [Related]
17. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
Ram M; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
[TBL] [Abstract][Full Text] [Related]
18. Immunological basis of melanoma-associated vitiligo-like depigmentation.
González R; Torres-López E
Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
[TBL] [Abstract][Full Text] [Related]
19. Melanoma and Vitiligo: In Good Company.
Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]